Ikonisys Announces the Launch of Ikoniscope Max in Europe at the 36th European Congress of Pathology in Florence
09 Septembre 2024 - 8:00AM
Business Wire
Regulatory News:
Ikonisys (Euronext Growth Paris: ALIKO), a company
specializing in the early and accurate detection of cancers through
a unique, fully automated solution for medical analysis
laboratories, is proud to announce the launch of its latest
groundbreaking product in Europe, the Ikoniscope Max. This
cutting-edge automated digital microscope will be introduced on the
occasion of the 36th European Congress of Pathology, taking place
from September 7-11, 2024, in Florence, Italy.
The Ikoniscope Max is poised to set a new standard in digital
pathology, offering unmatched precision, speed, and automation.
Building on Ikonisys renown as the world’s leading technology in
automated fluorescence in situ hybridization (FISH), the Ikoniscope
Max is designed to meet the growing demands of high productivity
laboratories, enabling pathologists to deliver faster and more
accurate diagnoses.
"We are thrilled to introduce the Ikoniscope Max to the European
market," said Francesco Trisolini, COO of Ikonisys. "This
launch represents a significant milestone in our commitment to
advancing the field of pathology. The European Congress of
Pathology is a great opportunity to showcase the Ikoniscope Max,
and we are excited to engage alongside over 30 of Europe's leading
pathologists who will gather to experience this revolutionary
technology firsthand."
The launch event will be held in a dedicated location in
Florence, where these esteemed pathologists will have the exclusive
opportunity to interact with the Ikoniscope Max and see how it can
transform their diagnostic workflows.
During the upcoming event, the Company will also demonstrate a
groundbreaking diagnostic approach combining Liquid-Based Cytology
(LBC) as a first-line analysis with automated Fluorescence In Situ
Hybridization (FISH) as a second-line diagnostic tool.
By integrating LBC cytology with automated FISH, the process is
expected to significantly enhance the accuracy and efficiency of
early cancer detection. The first-level LBC analysis allows for
rapid and comprehensive initial screening, while the second-level
automated FISH provides deeper diagnostic insights, ensuring that
even subtle abnormalities are detected with precision. This dual
approach could drastically improve early cancer detection rates and
patient outcomes, especially in large-scale screening programs.
Attendees of the European Congress of Pathology are invited to
attend the Event to see the Ikoniscope Max in action and learn more
about its capabilities. Ikonisys experts will be available to
provide detailed demonstrations and answer any questions.
About Ikonisys Ikonisys SA is a cell-based diagnostics
company based in Paris (France), New Haven (Connecticut, USA) and
Milan (Italy) specialized in the early and accurate detection of
cancer. The company develops, produces and markets the proprietary
Ikoniscope20® and Ikoniscope20max® platforms, fully-automated
solutions designed to deliver accurate and reliable detection and
analysis of rare and very rare cells. Ikonisys has received FDA
clearance for several automated diagnostic applications, which are
also marketed in Europe under CE certification. Through its
breakthrough fluorescence microscopy platform, the company
continues to develop a stream of new tests, including liquid biopsy
tests based on Circulating Tumor Cells (CTC).
For further information, please go to
www.ikonisys-finance.com
Disclaimer This press release contains forward-looking
statements about the Company's prospects and development. These
statements are sometimes identified by the use of the future tense,
the conditional tense and forward-looking words such as "believe",
"aim to", "expect", "intend", "estimate", "believe", "should",
"could", "would" or "will" or, where appropriate, the negative of
these terms or any other similar variants or expressions. This
information is not historical data and should not be construed as a
guarantee that the facts and data set forth will occur. This
information is based on data, assumptions and estimates considered
reasonable by the Company. It is subject to change or modification
due to uncertainties relating to the economic, financial,
competitive and regulatory environment. This information contains
data relating to the Company's intentions, estimates and objectives
concerning, in particular, the market, strategy, growth, results,
financial situation and cash flow of the Company. The
forward-looking information contained in this press release is made
only as of the date of this press release. The Company does not
undertake to update any forward-looking information contained in
this press release, except as required by applicable law or
regulation. The Company operates in a competitive and rapidly
changing environment and therefore cannot anticipate all of the
risks, uncertainties or other factors that may affect its business,
their potential impact on its business or the extent to which the
materialization of any one risk or combination of risks could cause
results to differ materially from those expressed in any
forward-looking information, it being recalled that none of this
forward-looking information constitutes a guarantee of actual
results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240908154748/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94
94
NewCap Nicolas Merigeau Media Relations
ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024